東陽光藥(01558.HK):上半年淨利降58.57%至2.52億元
格隆匯8月21日丨東陽光藥(01558.HK)披露2020年半年度報告,報告期內,公司實現營業收入59.51億元,同比下降19.51%;歸屬於上市公司股東的淨利潤2.52億元,同比下降58.57%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.89億元,同比下降67.60%;基本每股收益0.084元。
報告期內,面對下游電子消費產品整體需求下滑,行業競爭加劇,公司憑藉自身過硬的核心競爭力,電子新材料板塊整體業績穩中有增,營業收入同比增長6.56%,其中電極箔產品出口訂單量及價格同比有所增長,實現營業收入同比增長5.37%。
公司氯鹼化工產品作為大宗基礎化工原材料,其下游應用廣泛,受全球經濟週期影響以及新冠疫情與中美貿易摩擦對下游產業的衝擊所帶來的影響明顯,產品價格大幅下滑;而新型環保製冷劑受下游空調行業需求疲軟的影響,銷量價格下滑,導致化工板塊整體營業收入同比下降37%。
醫藥製造方面,公司核心及主要營收來源產品可威(磷酸奧司他韋)為抗流感的處方藥,受新冠疫情影響,國內人口流動性下降以及公共衞生意識的加強,各級醫療機構門診量減少,處方量大幅下降,藥品銷量出現較大幅度下滑,導致醫藥製造整體營業收入同比下降32.78%,隨着國內疫情逐漸得到控制,門診量逐漸提升,治療需求會逐漸釋放,預計未來藥品銷量會逐漸恢復。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.